Genmab (GMAB) said Sunday that results from a phase 1b/2 trial of its experimental epcoritamab treatment in combination with other drugs in patients with relapsed/refractory diffuse large B-cell lymphoma showed an overall response rate of 87%.
The results cover patients who are eligible for autologous stem cell transplantation.
The company said results also showed a complete response rate of 65%, and a partial response rate of 23%.
Safety data from the trial showed a low-grade cytokine release syndrome and no discontinuations due to treatment-emergent adverse events, Genmab said.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。